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Abstract: Nicotinic acetylcholine receptors (nAChR) are widely distributed in neuronal and non-
neuronal tissues, where they play diverse physiological roles. In this review, we highlight the recent
findings regarding the role of nAChR in the respiratory tract with a special focus on the involvement
of nAChR in the regulation of multiple processes in health and disease. We discuss the role of nAChR
in mucociliary clearance, inflammation, and infection and in airway diseases such as asthma, chronic
obstructive pulmonary disease, and cancer. The subtype diversity of nAChR enables differential
regulation, making them a suitable pharmaceutical target in many diseases. The stimulation of the
α3β4 nAChR could be beneficial in diseases accompanied by impaired mucociliary clearance, and
the anti-inflammatory effect due to an α7 nAChR stimulation could alleviate symptoms in diseases
with chronic inflammation such as chronic obstructive pulmonary disease and asthma, while the
inhibition of the α5 nAChR could potentially be applied in non-small cell lung cancer treatment.
However, while clinical studies targeting nAChR in the airways are still lacking, we suggest that
more detailed research into this topic and possible pharmaceutical applications could represent
a valuable tool to alleviate the symptoms of diverse airway diseases.
Keywords: nicotinic acetylcholine receptors; airways; lung; respiratory tract; mucociliary clearance;
chronic obstructive pulmonary disease; asthma; lung cancer
1. Introduction
Nicotinic acetylcholine receptors (nAChR) are widely distributed in diverse neuronal
and non-neuronal tissues. They form various subtypes consisting of different subunit
combinations. In mammals, nine alpha subunits (α1-7, α9, α10), four beta subunits (β1-4),
and one delta (δ), gamma (γ) and epsilon subunit (ε) have been detected [1]. The α1,
β1, δ, γ, and ε subunits are restricted to the muscle [1]. The nAChR form predominately
ionotropic pentameric receptors permeable for Ca2+ and Na+, albeit with different affinities
depending on the nAChR subtype [1]. However, there is a notion that nAChR can also
have metabotropic functions, especially in immune cells. For example, in T cells, the α7
nAChR increase the intracellular Ca2+ level via protein kinase activation instead of being
permeable to Ca2+ [2].
In the respiratory tract, various subunits of nAChR have been detected. In rat tracheal
epithelium, all mammalian α subunits but α1 have been identified [3]. In mouse tracheal
epithelium, we have been able to discover the α3, α4, α5, α7, α9, α10, β2, and β4 subunits,
with the α3 and α10 subunits being the most abundant among all of the α subunits,
followed by the α4 and α7 subunits [4,5]. In an α7 reporter mouse strain, expression of
the α7 nAChR was specifically detected in the epithelial club cells and alveolar type II
cells [6]. In the mouse embryonic lung, the α7 as well as the α5 subunits play an important
role in lung development, as indicated by the strict regulation of transcription of both
subunits during lung morphogenesis [7,8]. In bronchial epithelial cells of rhesus macaques,
the α3, α4, α7, α9, α10, β2, and β4 subunits have been detected [9]. Surprisingly, various
nAChR subunits have also been found in human bronchial epithelial cells, namely the α3,
α5, α7, β2 and β4 subunits [10,11]. Additionally, a recent study detected almost all of the
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nAChR subunits, with the exception of α7, in adult human whole-lung samples from non-
smokers, which contained all types of tissues, including epithelia, muscle, connective, and
nervous tissue [12]. When the authors analyzed the epithelial samples of the large airways,
they found all of the subunits except α1, α2, α4, β1, β3, β4, and δ, whereas in the small
airways, they discovered all 16 subunits. Remarkably, the authors found differences in
the nAChR subunit expression between smokers and non-smokers, such as the expression
of the α7 subunit in whole-lung samples. The expression of α5, α7, α10, β2, and β3 was
mainly correlated with smoking. In addition to peripheral lung tissue and the airway
epithelium, nAChR are also present on the immune cells and nerve endings innervating
the airways [2,13]. Interestingly, one study also described the intracellular localization of
nAChR in the lung tissue in the outer mitochondrial membrane [14]. The authors were able
to detect the α3, α4, α7, β2, and β4 subunits with a sandwich assay using subtype specific
antibodies, with the α3 and β4 subunits being the most abundant in the lung. Though
these findings are very intriguing, in light of the well-recognized problems regarding the
specificity of the available antibodies for the detection of AChR [15,16], these findings
should be verified in terms of this aspect, including transgenic mice (knock-out, reporter
mouse strains or/and overexpressing mouse strains) other than α7 and β2 nAChR-deficient
mice. Nevertheless, studies that have been performed with keratinocytes have provided
clear evidence that α3, α5, α7, α9, α10, β2, and β4 nAChR are functional mitochondrial
proteins [17]. Taken together, all of the aforementioned studies show that while some
differences might exist between species in terms of the expression of the various nAChR
subunits, they seem to be broadly expressed and to play an essential role for the functions
of the respiratory tract. This is further underlined by a study that showed a correlation
between nAChR expression and lung function measured by FEV1 [18].
Generally, nAChR display a wide variety of effects and properties. This is based on
the multitude of subunits present in different cell types in the respiratory tract, which
results in various possibilities for the assembly of these subunits. For example, the α7 and
α9 subunits are able to assemble as homopentamers or to form functional heteropentamers,
such as α9α10 or α7β2 [19,20]. Additionally, heteropentameric receptors can adopt various
stoichiometries. The α7β2 nAChR may contain one, two, or three β subunits but needs
at least two α subunits to form functional receptors [19]. Other receptors can contain two
α subunits and three β subunits or three α subunits and two β subunits, as was shown
for the α3β4 nAChR expressed in HEK293 cells and in Xenopus oocytes as well as for the
α4β2 nAChR expressed in Xenopus oocytes [21,22]. These variants in the stoichiometries
result in different affinities to ACh for the α3β4 as well as the α4β2 nAChR [21,22] and
may have different pharmacological profiles, as shown for the α7β2 nAChR [19]. Recently,
a stoichiometry of 3α:2β subunits was determined for the nAChR in synapses between
motoneurons and Renshaw cells [23]. Additionally, nAChR properties can be modulated by
assembly with the α5 nAChR subunit to form, e.g., α3β4α5 or α4β2α5 nAChR, as recently
reviewed [24].
Acetylcholine (ACh) serves as an endogenous ligand for the nAChR. In the airways,
ACh may originate from two different sources: (a) neuronally from the innervating cholin-
ergic nerve endings [25] or (b) non-neuronally from cholinergic chemosensory tracheal
brush cells, which represent a rare epithelial cell type expressing the ACh synthesizing
enzyme choline acetyltransferase [26–28]. Additionally, nose solitary chemosensory cells
are cholinergic and express choline acetyltransferase [29]. The nAChR subtypes display
diverse physiological properties, as discussed in this review, since their function depends
on the subunit composition and on their affinity to their endogenous ligand ACh.
2. The Role of Nicotinic Acetylcholine Receptors in Mucociliary Clearance
In the airways, mucociliary clearance (MCC) is an essential innate immune process.
It serves to transport inhaled particles and pathogens out of the airways by a continuous,
orchestrated ciliary beat, thereby preventing infections. MCC is an evolutionarily conserved
mechanism that can be found throughout the animal kingdom and that is already present
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in corals [30]. In the airways, it consists of two components: a physical component resulting
from the ciliary beat of the ciliated epithelial cells and a chemical component defined by
the volume and viscosity of the airway surface liquid (ASL). The viscosity and height of
the ASL is mainly regulated by ion transport processes. The ASL is, in turn, composed of
the periciliary liquid surrounding the cilia and providing an optimal environment for the
beating of the cilia, which is covered by a mucus layer in which the inhaled particles and
pathogens are trapped and then transported out of the airways together with the mucus.
It has been known for a while that ACh is able to regulate mucociliary clearance by
influencing ciliary beat and ion transport processes. ACh and the agonist of the muscarinic
acetylcholine receptors, muscarine, have been shown to influence particle transport speed
in mouse tracheas, mainly via the M3 receptors [27,31]. The cholinergic action on ciliary beat
depends on intracellular Ca2+, protein kinase A, and protein kinase G [32,33]. Interestingly,
ACh is also able to regulate transepithelial ion transport processes, which was demonstrated
about 25 years ago in sheep trachea [34]. However, at that time, ACh was thought to
originate solely from neurons. With the idea that a non-neuronal cholinergic system
might also exist in the respiratory tract, ACh of a non-neuronal origin was shown to be
involved in the regulation of transepithelial ion transport, as investigated in mouse and pig
tracheal epithelium [35,36]. Not only muscarinic receptors but also nAChR are involved
in regulating mucociliary clearance. We have previously shown that in murine tracheal
epithelium, the activation of nAChR with nicotine opens apical Cl− and basolateral K+
channels, more precisely, TMEM16A and KCNQ1 via Ca2+ and cAMP dependent pathways
downstream of the α3β4 nAChR [4,5,37]. These studies point towards a metabotropic
rather than an ionotropic action of the nAChR, providing further evidence that the classical
picture of nAChR being ligand-gated ion channels needs to be revised. Recently, nAChR
have also been shown to influence the ciliary-mediated component of mucociliary clearance
by increasing cilia driven particle transport in murine tracheas via the same nAChR subtype,
namely α3β4, which is responsible for mediating the changes in ion transport processes [38].
These studies about nAChR and mucociliary clearance have been conducted in mice. In the
pig trachea, which is supposed to be a more relevant model with regard to the transfer of
results to humans, nicotine had no effect on tracheal epithelial ion transport [36]. Therefore,
one could argue that there might be no relevance for humans. However, a study performed
before the existence of a non-neuronal cholinergic system in the airways became widely
apparent showed that nicotine influences transepithelial ion transport and intracellular Ca2+
levels in human nasal epithelial cells [39]. This provided the first evidence of functional
nAChR in non-excitable cells. Additionally, the α7 nAChR is able to regulate ion channels,
mainly the cystic fibrosis transmembrane conductance regulator (CFTR) channel in human
airway epithelium [40]. Thus, in the case of studying the role of nAChR in mucociliary
clearance, the mouse seems to be a more relevant model for extrapolating the results to
humans than pig models are. However, of course, more detailed studies on the role of
nAChR in mucociliary clearance in humans are needed. Taken together, the studies in
mouse and human airway epithelium regarding the regulation of mucociliary clearance by
nAChR point towards nAChR, especially the α3β4 subtype, being a suitable therapeutic
target for the stimulation of the mucociliary clearance under disease conditions in which it
is impaired, such as in cystic fibrosis and in chronic obstructive pulmonary disease (COPD).
3. Nicotinic Acetylcholine Receptors in Asthma and Chronic Obstructive
Pulmonary Disease
Asthma and COPD are diseases of the respiratory tract, both of which are characterized
by an obstruction of the airways. The cholinergic system is of considerable interest in
these diseases since it is involved in bronchoconstriction, which is mediated by ACh
acting mainly at the muscarinic M3 receptor [41]. Taking this into consideration, it is not
surprising that anticholinergic therapy for muscarinic receptors has been discussed for
COPD as well as in asthma [42,43]. However, this is only part of the story, as these diseases
are not only characterized by airway obstruction but also by inflammation. A role for
cholinergic signaling for inflammatory processes has been well established for a mechanism
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called the cholinergic anti-inflammatory pathway. In this model, stimulation of the vagus
nerve inhibits inflammatory responses. Twenty years ago, the α7 nAChR had already been
identified as playing a critical role in the cholinergic anti-inflammatory pathway and as
being involved in anti-inflammatory effects [44]. A recent study revealed that α7 nAChR
acts via an activation of adenylyl cyclase 6 and a lipid raft-mediated endocytosis of TLR4
in a COPD mouse model and proposed the use of α7 agonists as a novel approach for
COPD treatment [45]. In line with this, another study revealed that IL6 and NO levels
were increased in the blood plasma of COPD patients with peripheral blood mononuclear
cells and that these levels were associated with impaired lung function. Both, IL6 and NO
were downregulated when patients were treated with GTS-21, an α7 nAChR agonist [46],
underlining the importance of nAChR-mediated anti-inflammatory action also for COPD in
humans. In a recent study, the same agonist was proven to be beneficial in a mouse model
of hyperoxia-induced acute inflammatory lung injury [47]. There, the activation of the α7
nAChR reduced the levels of high-mobility group box 1 (HMGB1), a protein secreted by
macrophages, monocytes, and dendritic cells in the airways and in the circulation. Another
hallmark of COPD is the dysfunction of airway smooth muscle cells, which contributes
to airway remodeling and obstruction [48]. In this context, it should be considered that
nAChR also play a role in airway smooth muscle proliferation. It has recently been
shown that nicotine-induced proliferation of airway smooth muscle cells is mediated by
α7 nAChR since α7 nAChR-specific siRNA and inhibition with the α7 nAChR antagonist
MG624 attenuated proliferation [49]. The α7 nAChR acted via a mechanism that involves
transient receptor potential (TRP) C6 channels and PI3K/Akt signaling [49]. Another study
found that the α5 nAChR mediates airway smooth muscle cell proliferation via TRPC3
channels [50]. Thus, targeting nAChR and, in particular, the α7 nAChR in COPD needs to
be controlled carefully. On the one hand, it might have beneficial effects by attenuating
inflammation, and on the other hand, it might have deteriorative effects by increasing
airway smooth muscle proliferation. Nevertheless, a combined therapy for activation of α7
nAChR to reduce inflammation and inhibition of α5 nAChR or TRPC3 channels to reduce
airway smooth muscle cell proliferation might represent a promising therapeutic approach
for COPD.
Similar to COPD, α7 nAChR-dependent signaling seems to play a role in asthma. In an
ovalbumin asthma mouse model, the membrane impermeable nAChR agonist 1,1-dimethyl-
4-phenylpiperazinium (DMPP) was able to attenuate the airway hyperresponsiveness,
a hallmark of asthma, and airway inflammation by reducing lymphocyte and eosinophil
numbers in the bronchoalveolar lavage fluid and tissue infiltration by mononuclear cells
and eosinophils [51]. Moreover, the eosinophilia was suppressed by normal α7 nAChR
signaling in wild-type mice compared to in mice with a mutated dysfunctional α7 nAChR
in asthma models with house dust mites or ovalbumin [52].
Besides eosinophilia, group 2 innate lymphoid cells (ILC2) play an important role
in asthma and allergic diseases in generating type 2 immune responses, as recently re-
viewed by Zheng and coworkers [53]. A recent study discovered that vagotomy reduced
the number of ILC2 in an ovalbumin-induced asthma model of allergic inflammation
and that this effect was dependent on α7 nAChR, as ILC2 numbers were increased in α7
nAChR-deficient mice [54]. Additionally, the application of an α7 nAChR agonist resulted
in reduced cytokine expression in ILC2, and attenuated ILC2-induced airway hyperreactiv-
ity [55]. In line with this, targeting the α7 nAChR with the specific agonists PNU-282987 or
GTS-21 reduced the ILC2 numbers in the bronchoalveolar lavage fluid, goblet cell hyper-
plasia, and the eosinophilic infiltration and thus attenuated airway inflammation in mice
treated with IL33 or the fungus Alternaria alternata to induce inflammation [56] Moreover,
type 2 immune responses can also be elicited by tracheal epithelial brush cells releasing
ACh upon activation with bitter taste receptor agonists or with bacterial substances [57].
However, the role of brush cells in asthma and COPD in humans remains elusive.
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4. Additional Functions of Nicotinic Receptors in the Respiratory Tract
Besides their role in mucociliary clearance, COPD, asthma, inflammation, infection,
and lung cancers, nAChR play other important roles in the physiology and pathophysiology
of the respiratory system. A rat model of ventilator-induced lung injury revealed that the
activation of the α7 nAChR with the agonist PNU-282987 prior to ventilation attenuated
the ventilator-induced injury [58]. In line with this, the activation of the cholinergic anti-
inflammatory pathway and especially of the α7 nAChR subunit has been previously
suggested as an alternative treatment for ventilator-induced lung injury [59]. Not only in
ventilator-induced lung injury but also in a model of acid-induced acute lung injury, the
stimulation of the α7 nAChR had beneficial effects by attenuating this type of lung injury,
as indicated by decreased pulmonary edema, reduced vascular permeability, and a lower
protein component in the bronchoalveolar lavage fluid [60]. The expression of collagen type
I in cultured primary mouse lung fibroblasts was found to be upregulated via α7 nAChR
stimulation in vitro [61]. In vivo treatment with nicotine increased the collagen type I
expression in wild-type but not in α7 nAChR-deficient mice, which points towards the
involvement of the α7 nAChR subunit in the inflammatory extracellular matrix remodeling
process in response to lung injury [61].
Previously, we have been able to show that nerve endings approaching the airway
epithelium and especially the chemosensory cholinergic brush cells in the airways also
express nAChR and, specifically, the α3 nAChR subunit [26]. In line with this, we were
able to show that the stimulation of taste 2 receptors in the airways by the bitter substance
denatonium led to a transient decrease in the respiratory rate and induced respiratory
events similar to cough reflexes in humans in a nAChR-dependent manner [27]. Cough and
defensive airway reflexes have been shown to be dependent on nAChR [62]. However, the
role of brush cells for nAChR-dependent nerve activation in humans needs to be elucidated.
5. The Role of Nicotinic Acetylcholine Receptors in Monocytes and Macrophages
In addition to the presence of α7 nAChR in ILC2 cells, nAChR are also expressed in
monocytes and macrophages, both of which are immune cell types that are widely present
in the respiratory tract and particularly in the alveolar region. Alveolar macrophages play
a key role in the innate immune response elicited by inhaled pathogens or particles. In rat
alveolar macrophages, several subunits of nAChR have been detected, such as the α3, α5,
α9, α10, β1, and β2 subunits. Therefore, diverse functional subtypes may exist. However,
in these cells, no nAChR-dependent membrane currents or an increase in intracellular
Ca2+ levels due to nicotine or ACh application could be detected, pointing towards a
metabotropic action of nAChR in alveolar macrophages [13]. Indeed, an attenuation of
an increase of the intracellular Ca2+ concentration due to purinergic signaling could be
observed in this study when the nAChR in the alveolar macrophages were activated by
nicotine prior to stimulation with ATP, indicating that the nAChR on alveolar macrophages
are functional while not forming ligand-gated ion channels themselves. The assumption
that the nAChR in the macrophages are metabotropic is supported by a study with peri-
toneal macrophages, where the α7 nAChR was activated by the Janus kinase 2 pathway [63].
Moreover, the expression of the α7 nAChR in mouse alveolar macrophages was clearly
shown by observing fluorescence in a tau-GFP reporter mouse strain (α7G), in which
a bicistronic IRES:tau-GFP expression cassette was added to the 3′ end of the α7 nAChR
transcript [6]. The α7 nAChR in the alveolar macrophages seem to play an important role
in acute lung injury. In a lipopolysaccharide (LPS)-induced model of acute lung injury, the
α7 nAChR agonist GTS-21 was able to prevent the lung injury and to decrease the number
of alveolar macrophages and their production of pro-inflammatory cytokines [64]. Similar
results were obtained using the α7 nAChR agonist PNU-282987 [65]. Strikingly, not only
do the α7 nAChR on the macrophages play an anti-inflammatory role but the α7 nAChR in
the airway epithelium are also involved in cytokine and chemokine production after LPS
challenge [6]. Taken together, this clearly shows the importance of the role of α7 nAChR
on immune cells.
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The expression of the α7 nAChR has been shown for peripheral blood mononuclear
cells [44]. A population of migrating monocytes has been identified in the lung [66]. The
expression of α7 nAChR was detected in the human monocyte cell line THP-I and in
monocytes from smokers [67]. However, the α7 nAChR is not the only nAChR subtype that
can be found in monocytes. A metabotropic role was detected for the α9 and α10 subunit
containing nAChR in mouse monocytes [68]. Upon activation with phosphocholine, these
receptors inhibited the P2X7 ATP receptors, which resulted in a repression of the ATP-
dependent release of the pro-inflammatory cytokine interleukin-1β (IL-1β) and thus in an
ATP-dependent inflammasome activation. The effect of nAChR on the ATP-induced release
of IL-1β has been elucidated in detail by Grau and co-workers and is described in the
following paragraph [69–74]. The authors discovered that the monocytic α7, α9, and α10
nAChR subunits inhibited the IL-1β release when activated by phosphocholine, lysophos-
phocholine, and glycerophosphocholine. The α7 nAChR subunit was only marginally
involved in this metabotropic effect [69]. This effect seems to act by a feedback loop since
the C-reactive protein, which is produced in in response to increased IL-1β levels and binds
to phosphocholine, inhibited the ATP-induced IL-1β release via nAChR [70]. Additionally,
alpha-1 antitrypsin, a serine-protease that protects the human body from excess enzyme
activity in inflammation, was able to inhibit ATP-dependent IL-1β release in monocytes
via a mechanism that involves nAChR [71]. Moreover, this phenomenon is not only rele-
vant for monocytes but is also relevant for the respiratory tract [72]. Phosphocholine and
phosphocholine-modified lipooligosaccharides from Haemophilus influenzae were able to
inhibit IL-1β release in the lung adenocarcinoma epithelial cell lines A549 and Calu-3 as
well as in precision-cut lung slices [72]. Monocytes in the lung are constantly exposed to
surfactant. Interestingly, the surfactant component dipalmitoylphosphatidylcholine was
able to inhibit ATP-dependent IL-1β release via nAChR in monocytes [73].Thus, this com-
ponent could represent an important endogenous regulator of inflammation. In contrast to
this, the amyloid beta peptide Aβ1-42 overrode the anti-inflammatory effects of nAChR
in monocytes [74]. Taken together, nAChR-dependent inflammasome inhibition creates
further evidence for the importance of the anti-inflammatory action of nAChR and renders
the α9α10 nAChR in monocytes and the respiratory tract a suitable pharmaceutical target
for the inhibition of excessive inflammatory response.
6. The Role of Nicotinic Acetylcholine Receptors in Infections
Given the presence of nAChR in monocytes and macrophages and their ability to
influence immune responses, it is not surprising that nAChR also play a role in infectious
diseases. In lung epithelial cells and macrophages infected with Mycobacterium tuberculosis,
nicotine treatment led to a reduction in several cytokines and chemokines such as IL-6, IL-8,
IL-10, tumor necrosis factor α, C-C chemokine ligand (CCL) 2, CCL5, and C-X-C chemokine
ligand (CXCL) 9 or CXCL10 in an nAChR-dependent manner [75]. Consistent with this, an
inhibitory action of the α7 nAChR on cytokine production after Toll-like receptor activation
in human monocytes was previously described [76]. In addition to these anti-inflammatory
effects on the cytokines, an inhibitory effect of nicotine on the expression of antimicrobial
peptides in type II pneumocytes and airway basal epithelial cells could also be observed
when these cells were infected with M. tuberculosis [77]. This resulted in the increased
growth of M. tuberculosis in type II pneumocytes [77]. However, while promoting the anti-
inflammatory effects of nAChR by targeting them pharmaceutically might be beneficial in
airway diseases with excessive inflammation in the stage before bacterial infection, such as
acute lung injury, COPD, asthma, and even cystic fibrosis, targeting nAChR in infectious
diseases where cytokine production and the production of antimicrobial peptides is crucial
might be disadvantageous.
Since last year, the role of nicotine in COVID-19 has been controversially discussed.
A study from Lupacchini and co-workers concluded that nicotine aggravates SARS-CoV-2
infections [78]. This assumption is based on the increased proliferative effect of nicotine
and a nAChR-dependent upregulation of ACE2, as ACE2 has previously been shown to
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play a role in COVID-19 infection [79]. However, experiments with SARS-CoV-2 infection
in combination with nicotine need to be performed in future studies in order to better
support the conclusion of the authors. In contrast, Miyara and co-workers found a lower
proportion of smokers amongst COVID-19 patients than in the general population [80].
This study has strengths because it is based on direct interviews with patients and by
separating inpatients and outpatients. However, it also has limitations. It is a single-center
study, and the authors excluded patients in intensive care units [80]. Nevertheless, a recent
review has suggested the nicotinic cholinergic system as a possible therapeutic target based
on the anti-inflammatory properties of nicotine to counteract the cytokine storm observed
in severe COVID-19 cases and on its neuroprotectant and mood improvement effects [81].
Since the role of nicotine in COVID-19 disease has recently been reviewed elsewhere [81,82],
it will not be discussed further and in more detail in the present review article. Thus, with
the recent emergence of SARS-CoV-2 virus resulting in a severe pandemic, it has become
evident that nAChR also play a role in viral infectious diseases.
7. The Role of Nicotinic Acetylcholine Receptors in Lung Cancer
So far, the effects of nAChR and especially of the α7 nAChR on cell proliferation and
their role in lung cancer have been extensively studied and recently reviewed in detail [83].
Therefore, this paragraph aims to highlight only a few key findings regarding the role
of nAChR in lung cancer. In recent years, a specific role of the α7 nAChR in lung cancer
emerged since α7 nAChR mediated cell proliferation via a mechanism that involved β-
arrestin-dependent signaling with a downstream Src activation and an interaction with
Rb-Raf-1, which is elevated in non-small cell lung cancers [84]. The activation of this
metabotropic α7 nAChR signaling pathway resulted in the increased proliferation of non-
small cell lung cancer cells due to mitogenic effects on these cells [84]. Another study
suggested that the α7 nAChR gene was upregulated via the transcription factors E2F1
and STAT1 when non-small cell lung cancer cells were stimulated with nicotine [85].
Furthermore, an α7 nAChR-dependent activation of the MEK/ERK signaling pathway
was found to play a role in non-small cell lung cancer progression, especially during
epithelial–mesenchymal transition, in tumor growth, and in vimentin expression [86,87].
In conclusion, inhibiting the α7 nAChR and its various pathways that are involved in lung
cancer seems to be a promising strategy to combat lung cancer.
In addition to α7 nAChR, α9 nAChR are also involved in lung cancer and promote
nicotine-induced proliferation in the A549 lung adenocarcinoma cell line via Akt- and ERK-
dependent pathways [88]. In the bronchial epithelial cell line BEPD2, different variants
of the α9 nAChR have been identified due to naturally occurring polymorphisms [89].
An analysis of the function of these isoforms by overexpression revealed that one variant
(full length S442 protein) increased cell proliferation and transformation, while another
variant (full length N442 protein) did not influence the proliferation but reduced the
transformation of the human bronchial epithelial cell line BEP2D. A truncated form of α9
nAChR decreased proliferation as well as transformation [89]. This indicates thatα9 nAChR
polymorphism is an important factor determining increased susceptibility to lung cancer
development. Furthermore, the gene cluster encoding the α5, α3, and β4 nAChR subunits
plays an important role in lung cancer [90]. In non-small cell lung cancer, the activation of
the α5 nAChR induces the expression of the hypoxia-inducible factor 1α and the vascular
endothelial growth factor via the ERK1/2 and PI3K/Akt pathways involved in tumor cell
proliferation [91]. Supportively, the α5 nAChR and the hypoxia-inducible factor 1αwere
both upregulated in non-small cell lung cancer cells [91]. In the lung adenoma cell line
A549, α5 nAChR have been shown to activate cell migration and cell invasion [92]. In mice
injected with A549 cells stably suppressing α5 nAChR, tumor growth development was
reduced upon α5 nAChR suppression [93]. As a downstream mechanism for α5 nAChR
in nicotine-induced lung cancer, JAK2/STAT3 has been identified [94]. More recently it
was also shown that Jab1/Csn5 expression was correlated with α5 nAChR expression in
lung cancer and that it increased the expression of N-cadherin and vimentin, which is
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indicative for an induction of epithelial-mesenchymal transition [95]. Taken together, these
studies show that inhibiting α5 nAChR might represent a promising target for therapy for
nicotine-induced non-small cell lung cancer.
Interestingly, the subcellular localization of nAChR also seems to play a role in the
effects of nAChR on lung cancer progression. Chernyavsky and coworkers [96] found
that cytoplasmic membrane nAChR had a growth-promoting effect on lung cancer tumors
by synergizing with growth factors, while mitochondrial nAChR were involved in the
anti-apoptotic action of nicotine, further contributing to tumor progression.
8. Metabotropic Signaling of Nicotinic Acetylcholine Receptors
Often, the different properties of the nAChR resulting from variable subunit compo-
sition and stoichiometry have been characterized based on ionotropic receptor functions.
However, this is only part of the story, as there is increasing evidence for metabotropic
signaling in nAChR as an important and interesting new area of research, as described
above. However, the exact mechanisms of metabotropic signaling, especially in the respira-
tory tract, are not fully elucidated. Several mechanisms of metabotropic signaling have
been attributed to α7 nAChR. In the brain, α7 nAChR have been shown to form complexes
with G proteins [97]. The activation of these receptors induces a Gαq-, phospholipase Cβ2-
(PLCβ2) and inositol 1,4,5 trisphosphate- (IP3) dependent release of Ca2+ from intracellular
stores [97] (Figure 1). In addition to mobilizing intracellular Ca2+, G protein-dependent
signaling of α7 nAChR can also lead to an activation of the RhoA GTPase, which in-
hibits neurite growth [98]. In the airways, we have shown that the activation of α3β4
nAChR leads to a release of Ca2+ from intracellular stores, resulting in an activation of the
TMEM16A chloride channel [5]. This increase in the intracellular Ca2+ levels has additional
effects on soluble adenylyl cyclases, leading to a rise of intracellular cAMP and protein
kinase A activation [5,37] (Figure 1). However, the mechanism that augments the IP3
receptor-dependent increase in intracellular Ca2+ remains unknown. Based on the existing
literature, there might be two possibilities: either the α3β4 nAChR could be coupled to
G proteins, as shown for neuronal α7 nAChR in the hippocampus, prefrontal cortex, and
striatum [97], or they could be coupled to β-arrestin1, the tyrosine kinase Src and 14-3-3η
leading to PLC activation, as it has been recently shown for α4β2 nAChR in transfected
HEK293 cells [99]. In line with this, in mitochondria isolated from the squamous lung
cell carcinoma line SW900, the α7 nAChR subunit was found to be associated with the
phosphoinositide 3-kinase (PI3K) and the β4 subunit with Src [100].
Additionally, the association of α7 nAChR with Janus kinase 2 (JAK2) has been
described, and this association leads to activation of the signal transducer and activator
of transcription 3 (STAT3), resulting in a localization of STAT3 to the nucleus in neuronal
mypHoA-POMC/GFP cells, where it then serves as transcription factor [101] (Figure 1).
However, α7 is not the only nAChR coupled to JAK2. Additionally, α4β2 nAChR in
stably transfected SH-EP1 neuroblastoma cells are coupled to the JAK2/STAT3 pathway,
thereby inhibiting the transcription factor NFκB [102] (Figure 1). Although some of the
metabotropic signaling mechanisms of nAChR have only been described in neuronal cells,
it is likely that the non-neuronal nAChR of the respiratory tract might also signal via these
pathways and might be coupled to G proteins, β-arrestin, JAK2, or Src.
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I ri ary bronchial epithelial cell cultures from rhesu macaques, Lynx1 formed a complex
with α7 nAChR and led to the inhibition of AChR-depend t signali g [104]. Due to
the negative regulation of Lynx1 on AChR activity, especially through the inhibition
of B ergic- ediated ucin upregulation, Lynx1-mimetics have been suggested as
potential treatment options in asthma and COPD [105]. Additionally, Lynx1 may have
beneficial effects in preventing lung cancer endogenously since the increased expression of
Lynx1 in A549 lung cancer cells decreased the proliferation, and the inverse knockdown
of Lynx1 in these cells led to an increased proliferation [105]. The mechanism of action of
Lynx1 on α7 nAChR in A549 cells involved PKC/IP3 signaling as well as the MAP/ERK,
p38, and JNK pathways, which then resulted in cell cycle arrest and apoptosis [106].
Supportively, in squamous lung cell carcinomas, Lynx1 expression was much lower than
in healthy lung tissue [105].
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Another example for a modulatory protein expressed in the respiratory tract, especially
in ciliated bronchial epithelial cells of mice, is SLURP-1 [107]. In an asthmatic mouse model,
SLURP-1 expression was downregulated, suggesting a protective role for SLURP-1 in
preventing airway remodeling under proinflammatory conditions via the upregulation of
α7 nAChR activity [108]. In cultured human bronchial epithelial cells, SLURP-1 suppressed
the production of the proinflammatory cytokines IL-6 and TNF-α [109]. Interestingly,
SLURP-1 seems to have protective effects in lung cancer, as it abolishes the proliferation
of A549 cells, prevents the downregulation of PTEN expression, an important tumor
suppressor, as well as the up-regulation of α7 nAChR expression [110]. Besides interacting
with α7 nAChR, SLURP-1 also forms complexes with the receptor tyrosine kinases EGFR
and PRDFRα in A549 cells [111]. The interactions of SLURP-1 with these three proteins
down-regulates the migration of A549 cells.
Conclusively, members of the Ly6/uPAR family such as Lnyx1 or SLURP-1, including
their synthetic analogues, are promising options for therapeutically targeting lung cancer
or asthma.
10. Therapeutical Implications for Nicotinic Receptors in the Airways
The various subunits detected in the respiratory tract and especially in the airway
epithelium results in the combination of a large variety of nAChR subtypes with different
ligand affinities [1]. These subtypes have different functions, as previously described in
this review. Thus, selectively targeting these subtypes in the respiratory tract by inhalative
medicines or by cell targeted therapies for specific cell types could be beneficial. Until
now, anticholinergics targeting muscarinic acetylcholine receptors are widely used for
treating asthma and COPD [112]. However, while promising in vivo experiments for
modulating nAChR in the respiratory tract have been performed in mouse studies, as
summarized in this review, clinical studies in humans are still missing. For example, PNU-
282987 has emerged as a potential candidate for modulating α7 nAChR, as convincingly
demonstrated in mice [56]. Additionally, GTS-21 could be another candidate for targeting
α7 nAChR, as it showed promising effects on peripheral blood mononuclear cells isolated
from samples of COPD patients and healthy controls [46]. However, targeting nAChR in
the respiratory tract is not trivial because potential candidates may exclusively work in
the respiratory tract and not in other organs, so they need to be suitable for inhalation. It
should also be considered that in an ideal situation, the nAChR on the apical cytoplasmic
membrane may be available for inhalative therapies. The specific targeting of basolateral
or mitochondrial nAChR would be even more challenging since the compounds need to
be membrane permeable in order to access the receptors at the desired location, but at the
end, this might also lead to unfavorable systemic effects. Furthermore, when screening
for potential targeting candidates, different stoichiometries of the nAChR subtypes have
to be taken into account. So far, nAChR, especially the α7 nAChR subtype, are being
targeted pharmaceutically to treat diseases such as schizophrenia and autism in clinical
trials [113–116]. While specific agonists and antagonists exist for α7 nAChR, it could be of
considerable interest to develop specific modulators for the other nAChR subtypes that
are potentially of therapeutical interest in the respiratory tract, such as the α3β4 or α5
nAChR. Another difficulty is the need for cell type specific therapies, as the α7 nAChR in
lung cancer cells should be inhibited, while their activation in alveolar macrophages and
epithelial cells could be useful in order for them to exert their anti-inflammatory properties.
Despite the obstacles that have yet to be overcome, nAChR represent promising drug
targets for airway disease therapies, as shown by encouraging studies in mice [46,56].
11. Conclusions
Taken together, nAChR play an important role in physiological processes as well
as in diseases in the respiratory tract. They are an interesting pharmaceutical target for
alternative therapies. However, which receptor subtype should be selectively activated
or inhibited needs to be carefully elucidated depending on the disease-specific circum-
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stances. The activation of the α3β4 nAChR could be beneficial in diseases with impaired
mucociliary clearance, such as COPD, asthma, or even cystic fibrosis (Figure 2), while the
activation of the α9α10 nAChR in immune cells or α7 nAChR in alveolar macrophages and
lung epithelial cells might be helpful to ameliorate acute lung injury, COPD, and asthma
by reducing airway inflammation (Figure 2). In contrast to this, α5 nAChR should be
inhibited rather than activated in order to reduce the cell proliferation of non-small cell
lung cancer cells or of airway smooth muscle cells in COPD (Figure 2). The inhibition
the α7 nAChR might also be useful in these conditions in tumor cells (Figure 2). Thus,
the targeted activation of the α3β4 nAChR exclusively in the respiratory tract—due to its
high expression also in the brain—and the inhibition of the α5 nAChR specifically in lung
tumors could be interesting therapeutic strategies to follow. The targeting the α7 nAChR
should be considered cautiously, as it might have beneficial effects, e.g., the reduction
of inflammation upon activation, or worsening effects, e.g., increased cell proliferation.
Overall, the development of cell-targeted therapies in recent years, e.g., for non-small-cell
lung cancer [117], also presents a large amount of hope for other diseases of the respiratory
tract. More preclinical and clinical studies are needed to elucidate the broad impact of
nAChR in the respiratory system.
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